Markets

WuXi PharmaTech (WX) in Focus: Stock Falls 6.4% - Tale of the Tape

WuXi PharmaTech (Cayman) Inc. ( WX ) saw a big move last session, as the company's shares fell over 6% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This continues the most recent downtrend for WX, as the stock is down nearly 15% since May 22.

This Medical company has seen a flat track record when it comes to current year estimate revisions, as there has been no revision on either side over the past few weeks. The consensus for earnings estimate hasn't been in a trend either. This recent price action is discouraging, so make sure to keep a close watch on this firm in the near future, and especially on earnings estimates following the recent slump.

WX currently has a Zacks Rank #5 (Strong Sell) while its Earnings ESP is 0.00%.

Some better-ranked stocks in the Medical Drugs industry include Ariad Pharmaceuticals Inc. ( ARIA ) , Aeolus Pharmaceuticals Inc. ( AOLS ) and Aerie Pharmaceuticals, Inc . ( AERI ) . All these stocks carry a Zacks rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

WUXI PHARMATECH (WX): Free Stock Analysis Report

ARIAD PHARMA (ARIA): Free Stock Analysis Report

AERIE PHARMACT (AERI): Get Free Report

AEOLUS PHARMACT (AOLS): Get Free Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

AOLS AERI

Other Topics

Investing Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More